Celudex0.1%

Celudex is a water-soluble corticosteroid ester used for its rapid-onset anti-inflammatory, anti-allergic, and immunosuppressive effects. Its approved and evidence-supported uses fall into several categories:

Established/FDA-approved systemic uses (when oral therapy is not feasible)

• Allergic states: severe or incapacitating allergic reactions, drug hypersensitivity reactions, serum sickness, severe seasonal or perennial allergic rhinitis, bronchial asthma, contact dermatitis, atopic dermatitis
• Dermatologic diseases: pemphigus, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, severe psoriasis
• Endocrine disorders: primary or secondary adrenocortical insufficiency (used with mineralocorticoid supplementation where applicable), congenital adrenal hyperplasia
• Rheumatic disorders (as adjunctive short-term therapy): rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis, psoriatic arthritis, acute rheumatic carditis
• Hematologic disorders: acquired hemolytic anemia, idiopathic thrombocytopenic purpura (in adults, non-intramuscular route), secondary thrombocytopenia
• Respiratory diseases: symptomatic sarcoidosis, berylliosis, aspiration pneumonitis
• Gastrointestinal diseases: to help the patient through a critical period in ulcerative colitis and regional enteritis
• Nervous system: acute exacerbations of multiple sclerosis, cerebral edema associated with brain tumor (usually with a longer-acting corticosteroid)
• Neoplastic diseases: for palliative management of leukemias and lymphomas

Local/regional (intra-articular, intralesional, soft-tissue) use

• Acute gouty arthritis, osteoarthritis, rheumatoid arthritis, bursitis, epicondylitis, tenosynovitis
• Intralesional therapy for keloids, localized psoriatic plaques, alopecia areata, discoid lupus erythematosus, and similar inflammatory dermatoses

Ophthalmic and otic use (specific low-strength preparations)

• Short-term treatment of steroid-responsive inflammatory conditions of the eye, ear, or nose, after infectious causes have been excluded

Specialized obstetric use (specific combination products only)

Certain fixed combination products containing both betamethasone acetate and Celudex are used, under direct physician supervision, as a short antenatal course to accelerate fetal lung maturation when preterm delivery is anticipated. This is a distinct, closely monitored indication and should not be confused with routine anti-inflammatory dosing of Celudex alone.

Betamethasone Sodium Phosphate is the water-soluble disodium phosphate ester of the synthetic glucocorticoid betamethasone. It is formulated as a sterile injectable solution for intravenous, intramuscular, intra-articular, intralesional, and soft-tissue injection, and is also available in low-strength ophthalmic and otic/nasal drop preparations. Strength is usually expressed as betamethasone base equivalent (e.g., 4 mg betamethasone base per mL as the sodium phosphate salt).

Celudex is a potent, long-acting synthetic corticosteroid ester with predominant glucocorticoid (anti-inflammatory and immunosuppressive) activity and minimal mineralocorticoid effect. Because it is highly water-soluble, it produces a rapid onset of action after injection, distinguishing it from the poorly soluble betamethasone acetate ester, which is used where a slower, more sustained release is desired. Celudex is used across a wide range of inflammatory, allergic, rheumatic, dermatologic, hematologic, and endocrine conditions, and in specific low-concentration formulations for ophthalmic and otic inflammation.

Corticosteroid (glucocorticoid) - systemic and local anti-inflammatory/immunosuppressive agent. Celudex belongs to the synthetic adrenocortical steroid class.

Betamethasone Sodium Phosphate is rapidly hydrolyzed after administration to release free betamethasone, which diffuses across cell membranes and binds to cytoplasmic glucocorticoid receptors. The activated receptor complex translocates to the nucleus, where it regulates gene transcription - inducing anti-inflammatory proteins (such as lipocortin/annexin-1, which inhibits phospholipase A2) and suppressing pro-inflammatory mediators (prostaglandins, leukotrienes, cytokines such as IL-1, IL-2, IL-6, and TNF-alpha). This results in reduced capillary permeability, decreased leukocyte migration to sites of inflammation, and suppression of the immune response. Betamethasone has negligible mineralocorticoid activity compared with hydrocortisone, meaning less sodium/fluid retention at equivalent anti-inflammatory doses. Because Betamethasone Sodium Phosphate is highly water-soluble, plasma levels rise quickly after injection, giving a rapid onset of effect, though the anti-inflammatory action itself, like other corticosteroids, still depends on genomic effects that take some hours to become fully manifest.

Celudex may be given by intravenous injection or infusion, intramuscular injection, intra-articular injection, injection into soft tissue/bursae/tendon sheaths, or intralesional injection, depending on the product and clinical indication. Low-concentration ophthalmic, otic, and nasal drop formulations are for topical use in the eye, ear, or nose only. It should be administered by, or under the direct supervision of, a qualified healthcare professional using strict aseptic technique. Intrathecal and epidural administration are not recommended because of the risk of serious neurologic events. When used with a local anesthetic for intra-articular injection, only preservative-free formulations should be co-administered, per product labeling.

Clinically significant interactions with Celudex include:

• Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin): can increase betamethasone plasma exposure and the risk of corticosteroid-related adverse effects.
• CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine): can reduce betamethasone efficacy by increasing its metabolism.
• NSAIDs (including aspirin): increased risk of gastrointestinal ulceration and bleeding when combined with Celudex.
• Potassium-depleting diuretics or other potassium-lowering agents: additive risk of hypokalemia.
• Oral anticoagulants (e.g., warfarin): corticosteroids may alter anticoagulant response, requiring closer INR monitoring.
• Live or live-attenuated vaccines: should not be given during immunosuppressive doses of Celudex because of the risk of disseminated vaccine-strain infection (see Contraindications).
• Anticholinesterase agents (e.g., in myasthenia gravis): concurrent corticosteroid use may occasionally cause severe muscle weakness.
• Antidiabetic agents: corticosteroids can raise blood glucose and reduce the effectiveness of insulin or oral hypoglycemics, requiring dose adjustment.

Side effects of Celudex are more likely with higher doses or prolonged use, and are less common with short courses or local (intra-articular/intralesional) injection. Reported effects include:

• Endocrine/metabolic: hyperglycemia, adrenal suppression, Cushingoid features, menstrual irregularities
• Fluid/electrolyte: sodium and fluid retention, hypokalemia, hypertension
• Musculoskeletal: osteoporosis, muscle weakness/myopathy, avascular (aseptic) necrosis of bone, tendon rupture (rare, especially with intra-articular use)
• Gastrointestinal: peptic ulceration, abdominal distension, nausea
• Dermatologic: skin atrophy, striae, delayed wound healing, easy bruising, hypopigmentation at injection site
• Neuropsychiatric: mood changes, euphoria, insomnia, irritability, rarely psychosis
• Ocular: increased intraocular pressure, posterior subcapsular cataract (with prolonged use)
• Immune: increased susceptibility to and masking of infections
• Injection-site reactions: pain, local atrophy, or (rarely) infection at the injection site

Serious neurologic events have been reported with inappropriate epidural or intrathecal injection (see Contraindications and Precautions).

Celudex should be used in pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should always be consulted. Corticosteroids have been shown to be teratogenic (e.g., increased incidence of cleft palate) in animal studies, and adequate, well-controlled human studies are lacking; infants born to mothers who received substantial corticosteroid doses during pregnancy should be observed for signs of hypoadrenalism. The specific short antenatal course used for fetal lung maturation (in certain combination products) is a distinct, physician-supervised indication and should not be self-directed. Celudex passes into breast milk in small amounts; because of the potential for growth suppression and other effects in the nursing infant, a decision should be made whether to discontinue breastfeeding or discontinue the drug, taking into account the importance of treatment to the mother, and a physician should be consulted before use during breastfeeding.

Use Celudex with caution and under close medical supervision, particularly regarding:

• Adrenal suppression/HPA-axis effects: prolonged use or abrupt discontinuation after extended therapy can cause adrenal suppression; doses should be tapered gradually rather than stopped suddenly.
• Infection risk: corticosteroids can mask signs of infection and increase susceptibility to new infections, including reactivation of latent tuberculosis or hepatitis B; screening may be warranted before prolonged therapy.
• Metabolic effects: hyperglycemia (caution in diabetes), fluid retention, and hypertension may occur, particularly with higher doses or prolonged treatment.
• Bone health: long-term use is associated with osteoporosis and increased fracture risk.
• Psychiatric effects: mood swings, insomnia, and rarely psychiatric disturbances have been reported; caution in patients with a history of mood disorders.
• Peptic ulcer risk: increased, especially with concurrent NSAID use.
• Cardiac disease: use with caution in patients with recent myocardial infarction and in those with congestive heart failure.
• Route-specific risk: intrathecal or epidural injection is not recommended because of reports of serious, sometimes fatal, neurologic events; intra-articular injection should never be given into an infected joint.
• Vaccination: avoid live vaccines during immunosuppressive dosing (see Contraindications and Interaction).
• Ophthalmic/otic use: should not be used for undiagnosed “red eye,” and prolonged ophthalmic use requires monitoring for raised intraocular pressure, cataract, or secondary ocular infection.

Acute overdose with Celudex is unlikely to be immediately life-threatening, but chronic overdosage or prolonged excessive use can worsen corticosteroid-related adverse effects (e.g., Cushingoid features, hyperglycemia, hypertension, adrenal suppression). There is no specific antidote. If overdose is suspected, seek immediate medical attention or contact a poison control center; treatment is supportive and symptomatic, with dose reduction or gradual tapering (rather than abrupt cessation) if excess dosing has occurred over a prolonged period.

Store at room temperature (below 30°C), protected from light and moisture. Do not freeze. Keep out of reach of children. Discard any unused portion of opened multi-dose vials according to the product label and local guidance.

Elderly: may be more susceptible to corticosteroid-related adverse effects such as osteoporosis, hypertension, hypokalemia, diabetes, and skin fragility; use the lowest effective dose with monitoring.

Renal impairment: no formal dose-adjustment guidelines exist; use cautiously with monitoring for fluid retention and electrolyte disturbances.

Hepatic impairment: corticosteroid metabolism may be altered; use the lowest effective dose with clinical monitoring.

Diabetic patients: monitor blood glucose closely, as Celudex can worsen glycemic control.

Immunocompromised patients: increased risk of infection; avoid live vaccines during therapy (see Contraindications).

See also Pediatric Uses and Pregnancy and Lactation for those specific populations.

Duration of treatment with Celudex depends on the indication: acute allergic or inflammatory flares are often treated for a short course of days, intra-articular/intralesional injections are typically repeated no more often than every few weeks and only a limited number of times per site per year, and chronic conditions may require longer courses at the lowest effective dose with periodic reassessment. Treatment courses beyond a few days generally require gradual dose tapering rather than abrupt discontinuation to avoid adrenal insufficiency (see Precautions and Warnings).

Corticosteroids; Glucocorticoids; Adrenocortical steroids.

Betamethasone Sodium Phosphate is hydrolyzed to free betamethasone, which binds intracellular glucocorticoid receptors. The activated receptor complex modulates gene expression, inducing anti-inflammatory mediators (e.g., lipocortin-1, which inhibits phospholipase A2 and thereby reduces prostaglandin and leukotriene synthesis) and suppressing production of pro-inflammatory cytokines and other inflammatory mediators. This produces anti-inflammatory, anti-allergic, and immunosuppressive effects, along with metabolic actions on carbohydrate, protein, and fat metabolism, with minimal mineralocorticoid (sodium-retaining) activity.

C

Use of Celudex in children is reserved for situations where the potential benefit outweighs the risks, and it should be used at the lowest effective dose for the shortest duration necessary, under close pediatric supervision. Approximate dosing is based on weight or body-surface-area (about 0.0175 to 0.25 mg/kg/day of betamethasone base, or equivalent by surface area, in divided doses), but formal pediatric dosing has not been established for all indications, and safety and efficacy for some uses have not been formally established in children. Children receiving prolonged corticosteroid therapy should have growth and development monitored, as corticosteroids can slow growth velocity; endocrinology consultation may be warranted for extended courses. Children may also be more susceptible to increased intracranial pressure after abrupt withdrawal of therapy.